Literature DB >> 22271569

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Harry Sokol1, Laurent Beaugerie, Marc Maynadié, David Laharie, Jean-Louis Dupas, Bernard Flourié, Eric Lerebours, Laurent Peyrin-Biroulet, Matthieu Allez, Tabassome Simon, Fabrice Carrat, Nicole Brousse.   

Abstract

BACKGROUND: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide prospective observational cohort.
METHODS: In all, 680 gastroenterologists enrolled 19,486 patients with IBD (Crohn's disease in 60.3%) from May 2004 to June 2005. Follow-up ended on 31 December 2007. Available biopsy samples and surgical specimens from patients with PILD (n = 14) were centralized for review. The reference incidence of PILD in the general population was obtained from the Côte d'Or registry and was used as a comparator to assess the standardized incidence ratio (SIR). The influence of thiopurine exposure was explored in a nested case-control study.
RESULTS: In the CESAME population the crude incidence of PILD was 0.12/1000 patient-years, with a corresponding SIR of 17.51 (95% confidence interval [CI], 6.43-38.11; P < 0.0001). The risk was highest in patients exposed to thiopurines (SIR 49.52, 95% CI 13.49-126.8; P < 0.0001), while it did not reach statistical significance in patients naïve to thiopurines (SIR 4.83, 95% CI, 0.12-26.91; P = 0.37). The odds ratio associated with ongoing thiopurine exposure (vs. naïve) was 2.97 (95% CI, 0.30-infinity; P = 0.38). All 14 cases of PILD were non-Hodgkin's B-cell LD, 78.6% occurred in males, 85.7% arose in IBD lesions, and 45.5% were Epstein-Barr virus-positive. Eleven cases occurred in patients with Crohn's disease. Mean (SD) age at PILD diagnosis was 55.1 (5.6) years and the median time since IBD onset was 8.0 years (interquartile range, 3.0-15.8).
CONCLUSIONS: Patients with IBD have an increased risk of developing PILD.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271569     DOI: 10.1002/ibd.22889

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  21 in total

Review 1.  EBV-associated lymphoproliferative disorder involving the gastrointestinal tract which mimic IBD in immunocompetent patients: case reports and literature review.

Authors:  Yanhua Zhou; Yanlin Zhang; Haiying Zhao; Xuan Cui; Yongqiu Wei; Yongdong Wu; Shutian Zhang; Ye Zong
Journal:  Int J Colorectal Dis       Date:  2019-10-23       Impact factor: 2.571

2.  Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.

Authors:  María Chaparro; M Ramas; J M Benítez; A López-García; A Juan; J Guardiola; M Mínguez; X Calvet; L Márquez; L I Fernández Salazar; L Bujanda; C García; Y Zabana; R Lorente; J Barrio; E Hinojosa; M Iborra; M Domínguez Cajal; M Van Domselaar; M F García-Sepulcre; F Gomollón; M Piqueras; G Alcaín; V García-Sánchez; J Panés; E Domènech; E García-Esquinas; F Rodríguez-Artalejo; J P Gisbert
Journal:  Am J Gastroenterol       Date:  2017-05-23       Impact factor: 10.864

Review 3.  Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.

Authors:  Jordan E Axelrad; Simon Lichtiger; Vijay Yajnik
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

4.  Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota.

Authors:  Siddhant Yadav; Siddharth Singh; W Scott Harmsen; Jithinraj Edakkanambeth Varayil; William J Tremaine; Edward V Loftus
Journal:  Mayo Clin Proc       Date:  2015-05-09       Impact factor: 7.616

5.  Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease.

Authors:  Heimo H Wenzl; Christian Primas; Gottfried Novacek; Alexander Teml; Anna Öfferlbauer-Ernst; Christoph Högenauer; Harald Vogelsang; Wolfgang Petritsch; Walter Reinisch
Journal:  Dig Dis Sci       Date:  2014-11-08       Impact factor: 3.199

Review 6.  Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era.

Authors:  Gerassimos J Mantzaris
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

7.  Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease.

Authors:  Neil R Moran; Bradley Webster; Kenneth M Lee; Judith Trotman; Yiu-Lam Kwan; John Napoli; Rupert W Leong
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

8.  Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation.

Authors:  Sameer Lapsia; Siva Koganti; Salvatore Spadaro; Ramona Rajapakse; Anupama Chawla; Sumita Bhaduri-McIntosh
Journal:  J Med Virol       Date:  2015-08-31       Impact factor: 2.327

Review 9.  Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.

Authors:  Grace Y Lam; Brendan P Halloran; Anthea C Peters; Richard N Fedorak
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 10.  Use of thiopurines in inflammatory bowel disease.

Authors:  Pascal Frei; Luc Biedermann; Ole Haagen Nielsen; Gerhard Rogler
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.